The influence of OKT3 therapy on hepatocellular carcinoma recurrence following liver transplantation. Clin Transplant 2010;24(4):E103-8
Date
12/25/2009Pubmed ID
20030681DOI
10.1111/j.1399-0012.2009.01179.xScopus ID
2-s2.0-77955725860 (requires institutional sign-in at Scopus site) 2 CitationsAbstract
INTRODUCTION: Cancer recurrence following orthotopic liver transplantation (OLT) for hepatocellular carcinoma (HCC) is a significant obstacle in up to 10-20% of recipients. Recent evidence suggests that anti-CD3 antibody (OKT3) therapy may be associated with increased rates of HCC recurrence.
METHODS: At the University of Colorado Transplant Center, 173 patients underwent OLT for end-stage liver disease with concomitant HCC between 1997 and 2008. Nine clinical and pathologic variables were analyzed to test the association between OKT3 therapy for steroid-resistant rejection (SRR) and HCC recurrence-free survival.
RESULTS: Overall, the rate of HCC recurrence in this cohort was low and comparable across treatment groups (8.7%). Multivariate analysis reveals that increasing tumor diameter and differentiation have a negative impact on HCC recurrence-free survival.
CONCLUSIONS: While several pathologic variables appear to influence outcome, we found no association between OKT3 therapy for SRR and HCC recurrence or survival.
Author List
Zimmerman MA, Kelly MA, Campsen J, Mandell MS, Wachs M, Bak T, Skibba A, Lancaster B, Kam IMESH terms used to index this publication - Major topics in bold
Carcinoma, HepatocellularFemale
Humans
Immunosuppressive Agents
Liver Neoplasms
Liver Transplantation
Male
Middle Aged
Muromonab-CD3
Neoplasm Recurrence, Local
Retrospective Studies
Survival Rate
Treatment Outcome
